Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway

Fig. 6

UCMSCs play a hypoglycemic role by regulating the activation of the PI3K/AKT signaling pathway. a Organ weight coefficient at 4 weeks after cell infusion. b Serum transaminase levels. c Hepatic level of SOD and H2O2. d H&E staining of liver tissue sections. Scale bar, 100 µm. e Immunohistochemical staining of IRS-1 in liver tissue. f Immunofluorescence staining of liver tissue GLUT4. G Western blot analysis of AKT, p-AKT, PI3K, p-P3K3, P53, GLUT4, Capase3, AS160, BAX, and BCL-2 expression levels in the livers of HFD-fed mice and T2DM, UCMSCs and UCMSCs/Mel after 6 weeks of treatment. Beta-actin was used as a loading control. h Quantitative analysis of the western blot results of G. NC (normal control); T2DM (Type II diabetic mellitus); UCMSC (hUC-MSCs); Mel (melatonin); ns (no significant). Data are mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page